A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects

Cardiovascular Therapeutics

Volumn 32, Issue 6, 2014, Pages 297-301

  Lunven, Catherine ^a   Paehler, Tobias ^b   Poitiers, Franck ^a   Brunet, Aurélie ^a   Rey, Jacques ^a   Hanotin, Corinne ^a   Sasiela, William J ^c  

^a SANOFI   (France)

^b Sanofi   (Germany)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Alirocumab; Cholesterol; Low density lipoprotein; Pharmacodynamics; Pharmacokinetics; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84911411495     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12093     Document Type: Article

References (10)

1. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156.
2. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-2353.
3. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-1900.
4. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
6. Roth EM, Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol 2014;10:183-199.
7. McKenney JM, Swergold GA, DiCoccio AT, et al. Dynamics between the monoclonal antibody alirocumab (SAR236553/REGN727), Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and low-density lipoprotein cholesterol (LDL-C) levels. 81st European Atherosclerosis Society Congress, 2013, Lyon, France.
8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118.
9. Farnier M, Kastelein JJ, Roth E, et al. Relationship between alirocumab, PCSK9, and LDL-C levels: results from the ODYSSEY MONO Phase 3 trial of alirocumab 75 mg every 2 weeks. 82nd European Atherosclerosis Society Congress, 2014, Madrid, Spain.
10. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesteremia: results of a 24-week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014;176:55-61.